{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Maldonado E"],"funding":["NCATS NIH HHS","NCI NIH HHS"],"pagination":["1793-1801"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11264598"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["4(7)"],"pubmed_abstract":["We sought to evaluate the efficacy of WEE1 inhibitor adavosertib in patients with solid tumor malignancies (cohort A) and clear cell renal cell carcinoma (ccRCC; cohort B). NCT03284385 was a parallel cohort, Simon two-stage, phase II study of adavosertib (300 mg QDAY by mouth on days 1-5 and 8-12 of each 21-day cycle) in patients with solid tumor malignancies harboring a pathogenic SETD2 mutation. The primary endpoint was the objective response rate. Correlative assays evaluated the loss of H3K36me3 by IHC, a downstream consequence of SETD2 loss, in archival tumor tissue. Eighteen patients were enrolled (9/cohort). The median age was 60 years (range 45-74). The median duration of treatment was 1.28 months (range 0-24+). No objective responses were observed in either cohort; accrual was hal"],"journal":["Cancer research communications"],"pubmed_title":["A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170)."],"pmcid":["PMC11264598"],"funding_grant_id":["UM1 CA186690","UM1 CA186717","UM1 CA186709","UM1 TR004906","UL1 TR001863","P30 CA093373","UM1 CA186689","UM1 CA186688"],"pubmed_authors":["Trikalinos NA","Maldonado E","Mahalingam D","Balido C","Aggarwal RR","Takebe N","Munster PN","Rathmell WK","Shapiro GI","Rodon J","Parikh M","Bergsland EK","Kalebasty AR","Ashworth A","Krings G","LoRusso P","Boerner SA","Burns TF"],"additional_accession":[]},"is_claimable":false,"name":"A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).","description":"We sought to evaluate the efficacy of WEE1 inhibitor adavosertib in patients with solid tumor malignancies (cohort A) and clear cell renal cell carcinoma (ccRCC; cohort B). NCT03284385 was a parallel cohort, Simon two-stage, phase II study of adavosertib (300 mg QDAY by mouth on days 1-5 and 8-12 of each 21-day cycle) in patients with solid tumor malignancies harboring a pathogenic SETD2 mutation. The primary endpoint was the objective response rate. Correlative assays evaluated the loss of H3K36me3 by IHC, a downstream consequence of SETD2 loss, in archival tumor tissue. Eighteen patients were enrolled (9/cohort). The median age was 60 years (range 45-74). The median duration of treatment was 1.28 months (range 0-24+). No objective responses were observed in either cohort; accrual was hal","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2026-06-02T09:09:07.071Z","creation":"2025-02-18T23:19:04.551Z"},"accession":"S-EPMC11264598","cross_references":{"pubmed":["38920407"],"doi":["10.1158/2767-9764.CRC-24-0213"]}}